risks and side effects of bpc-157 and tb-500 BPC-157: Miracle Healing Peptide or Hidden Danger? The Hidden Risks of BPC‑157:

Safety and Clinical Supervision Though the BPC-157 peptide is not FDA-approved for general medical use, there is ample evidence showcasing its effectiveness

But they have other beneficial properties, as well, to promote internal healing

More research is needed to understand these interactions and their impact on patient care

Because Tesamorelin uses a fixed dose for all 3 months while the Wolverine Blend escalates progressively, the two protocols have independent dose structures that are simply run in parallel

If you see an air bubble, flick the side of the syringe

Early evidence for the potential efficacy of this route was published in 1999, where 18 patients with B12 deficiency treated exclusively with 712 days of 2 mg of sublingual cobalamin daily had 4 times higher B12 levels compared to pre-treatment, reaching therapeutic ranges ( There have also been further studies comparing treatment outcomes from the sublingual route to the more established IM and oral routes